Healthcare Contract Development and Manufacturing Organization Market Size, Manufacturing Capacity, Sales Performance, Regulatory Approvals, Competitive Landscape, and Forecast

Revenue, 2025

USD 268.23 Bn

Forecast Year, 2035

USD 600.45 Bn

CAGR, 2026 - 2035

8.39%

Report Coverage

Global

What is Healthcare Contract Development and Manufacturing Organization Market Size?

The global healthcare contract development and manufacturing organization market size is estimated at USD 268.23 billion in 2025 and is predicted to increase from USD 291.03 billion in 2026 to approximately USD 600.45 billion by 2035, expanding at a CAGR of 8.39% from 2026 to 2035. The global healthcare contract development and manufacturing organization market is driving due to growing outsourcing of drug development and manufacturing, increasing biologics production, rising demand for specialized expertise, and expanding pharmaceutical and biotechnology pipelines worldwide.

Market Highlights

• North America led the global market with the highest market share of 42% in 2025.
• Asia Pacific region is estimated to expand the fastest CAGR between 2026 to 2035.
• By Services, the contract manufacturing segment held the largest market share in 2025.
• By Services, the contract development segment is expected to gain the highest market share with a CAGR of XX% between 2026 and 2035.

Market Overview

The healthcare Contract Development and Manufacturing Organizations (CDMOs) market includes service providers that support pharmaceutical, biotech, and device manufacturers in terms of R&D, process development, analytical examination, production of medicines, and product delivery. Companies working in the CDMO field assist their clients in speeding up the development processes and minimizing investments and operational costs.

The increasing outsourcing of drug development and production, the rise of biologics or cell and gene therapy pipelines, and that there is growing demands for flexible production capacity explains the growth of the CDMO market. Moreover, the increase in regulatory pressure pushes firms to partner up with the experienced CDMOs in order to comply with quality requirements and use modern production methods.

How Artificial Intelligence Transforming the field of Healthcare Contract Development and Manufacturing Organization Market excellence?

Artificial Intelligence transforms the field of healthcare CDMOs through the enhancement of efficiency in drug development, manufacturing, and quality control. Through the use of analytics powered by AI, process improvement efforts are accelerated, production variations are identified, as well as predictive maintenance. Machine learning algorithms also contribute to formulation developing, optimizing bioprocessing parameters, and enhancing the consistency of production batches. AI ensures quality assurance by automating inspection, detecting anomalies, and monitoring in real time. Furthermore, AI technology can facilitate demand forecasting and supply chain optimization, allowing production efficiency to improve above the current levels. Although CDMO market leaders have been on the set ground for a while, many pharmaceutical and biotech companies welcome new innovative opportunities provided by AI technology.

Healthcare Contract Development and Manufacturing Organization Market Growth Factors

• The healthcare contract development and manufacturing organization market is driven by the increased demand for specialist medical gadgets. A primary driver for the healthcare storage contract manufacturing industry in the growing population of older individuals and their inactive lifestyle. As a result, these variables will greatly boost the healthcare contract development and manufacturing organization market growth during the forecast period.
• The pharmaceutical industry's rise will aid the healthcare contract development and manufacturing organization market's expansion in the upcoming years. The increased support of contract development and manufacturing organizations in lowering the capital and operational expenses will assist the market in achieving maximum income in the near future.
• The healthcare contract development and manufacturing organization market will be driven in the next years by a boom in regulatory affairs, which are positive, and quality assurance services. Furthermore, increasing shipping costs and the danger of violation of intellectual property rights could stifle the healthcare contract development and manufacturing organization market expansion throughout the projection period.
• The healthcare contract development and manufacturing organization market is being driven forward by the expiration of medical device patents and increased rivalry among large businesses. In addition, the healthcare contract development and manufacturing organization market is being boosted by the increased desire for convenient devices.

Future Market Trends in Market

• The rise in the need for biologics, cell therapies, gene therapies, and new vaccines is compelling CDMO companies to extend their specialized manufacturing capabilities. Companies are investing in advanced containment facilities, single-use technology, and flexible production systems.
• Customers from the pharmaceutical and biotechnology industry are more focusing on integrated CDMO partners providing drug development, clinical manufacturing, commercial manufacturing along with regulatory support among other functions. It goes without saying that by opting for such service model gives you the chance to simplify the supply chains, lessen the expenses, speed the product launches, and create long lasting strategic partnership.
• The CDMO field is using endless on the rise of digital manufacturing technologies such as digital twins, electronic batch records, cloud monitoring, and advanced analytics. This technology makes it possible for the enterprises to enhance production visibility, gain real time decision-making, enhance the product quality, and ensure transparency in the manufacturing process.
• Nowadays the problem of sustainability is a pressing concern with the CDMO companies introducing energy efficient manufacturing, waste reduction or recycling. Hereby, the installation of sustainable processes assists the companies in complying with the regulations.

Market Outlook

• Market Growth Overview: The healthcare contract development and manufacturing organization market is expected to grow significantly between 2025 and 2034, driven by the rising outsourcing, growth in biologics and advanced therapies, and increasing research and development spending.
• Sustainability Trends: Sustainability trends involve green chemistry & sustainable processes, waste management & circular economy initiatives, and water conservation & pollution prevention.
• Major Investors: Major investors in the market include Thermo Fisher Scientific Inc., Labcorp, Novo Holding A/S, Catalent, Inc., Danaher Corporation, and Lonza Group Ltd.
• Startup Economy: The startup economy is focused on service specialization and vertical integration, next-generation equipment and process technology, and geographical expansion and cost competitiveness.

Market Scope

Segments Insights

Services Insights

In 2025, contract manufacturing dominated the market for healthcare contract development and manufacturing organization, accounting for the majority of revenue 74% in 2023. This is mostly wing to the pharmaceutical and medical device industries' strong penetration of contract manufacturing.

On the other hand, the contract development is expected to grow at fastest rate during the forecast period. The contract development has various advantages over in-house drug development, including access to industry specialists, shorter time to market, lower costs, and a greater concentration on core skills.

Regional Insights

U.S. Healthcare Contract Development and Manufacturing Organization Market Size and Growth 2026 to 2035

The U.S. healthcare contract development and manufacturing organization market size is estimated at USD 79.32 billion in 2025 and is predicted to be worth around USD 180.92 billion by 2035, at a CAGR of 8.6% from 2026 to 2035.

North America region accounted revenue share of 42% in 2025. The North America region's demand for healthcare contract development and manufacturing was boosted by the growth of the pharmaceutical industry. As a result, in terms of contract development and manufacturing of medical devices, North America's market is predicted to increase rapidly.

U.S. Healthcare Contract Development and Manufacturing Organization Market Trends

U.S. is a major contributor to the market in North America. The growing demand for biologics, rising investments in R&D activities, increased collaborations and M&A activities among pharmaceutical companies, government support, booming generic drug market and rising incidences of chronic diseases are driving the market growth. Adoption of advanced technologies such as AI-powered analytics, single-use bioreactors and continuous manufacturing by CDMOs are enhancing production capacity, quality control and regulatory compliance.

• For instance, in October 2024, NorthStar Medical Radioisotopes, LLC, inaugurated its state-of-the-art Radiopharmaceutical Contract Development & Manufacturing (CDMO) Facility in Wisconsin which will provide development services and dose manufacturing capacity for key medical radioisotopes, including Ac-225, Lu-177, Cu-64, Cu-67, and In-111 among others.

Asia Pacific Healthcare Contract Development and Manufacturing Organization Market Trends

Asia Pacific is anticipated to witness lucrative growth in the market over the forecast period. The market growth is driven by factors such as robust regulatory frameworks fostering innovation, need for compliance with quality standards to accelerate market reach, increased emphasis on development of complex drugs and medical devices growing demand for biosimilars and availability of cost-effective skilled workforce.

Furthermore, government initiatives attracting foreign investments, rising trend of outsourcing drug development and manufacturing activities, and surging demand for pharmaceutical [products with increasing healthcare expenditure are fuelling the market expansion.

China Market Trends

The Chinese healthcare contract development and manufacturing organization market is growing due to strong government support and increasing demand for outsourced pharmaceutical R&D and manufacturing. A primary trend involves the shift towards high-value services in biologics and HPAPIs, moving beyond traditional generics. Strategic capacity expansion and the adoption of advanced technologies like AI are key operational focus areas for major players.

Europe Healthcare Contract Development and Manufacturing Organization Market Trends

Europe's Healthcare market supported by well-built pharmaceutical infrastructure, cutting-edge technology, and the growing need for biologics, cell and gene therapy and sophisticated drugs. There is an increasing trend for companies to outsource their research, testing and manufacturing to achieve efficiency and lessen the time needed for commercialization. Thereby emergence of companies having necessary know-how, full range of services offered and significant automation investments is enhancing outsourcing environment in the region.

Germany Market Trends

Germany is blessed with an effective pharmaceutical market, educated workforce, and well-established manufacturing infrastructure. Growing investment in biologics and expensive drug manufacturing attracts pharmaceutical companies to deal with CDMOs.

MEA Healthcare Contract Development and Manufacturing Organization Market Trends

MEA healthcare CDMO market is witnessing expansion due to increasing investments into healthcare, pharmaceutical manufacturing relocation, and rising demand for economical medicines. Companies operating in the region are enhancing their capabilities in generic medicine production, sterile manufacturing and packaging as well as ensuring compliance with quality criteria.

UAE Market Trends

The UAE is starting to become a leading center of pharmaceutical manufacturing in the region, thanks to government healthcare initiatives, state-of-the-art manufacturing facilities, and international partnerships. The region is seeing investments in generics, sterile drugs, and pharmaceutical packaging that create opportunities for CDMO providers to expand their service offerings.

Latin America Healthcare Contract Development and Manufacturing Organization Market Trends

Latin America is seeing the advancement of its healthcare CDMO market, which is influenced by increased pharmaceutical production, growing demand for healthcare, and the rise in the use of outsourced development services. Local companies are improving their competencies in the sectors of generic drugs, formulation development, and contract manufacturing. The government's supported in establishing the necessary infrastructure for the local pharmaceutical industry and the measures to enhance the resilience of supply chain will also contribute to the growth of outsourcing opportunities in the region.

Brazil: Market Trends

Brazil is one of the main centers of pharmaceutical manufacturing in Latin America, owing to the large healthcare market and increasing production of pharmaceuticals in the country. The increasing demand for locally produced products and cooperation with multinational pharmaceutical companies are expanding the capabilities of the CDMO market in the country.

Value Chain Analysis

• Research & Development (R&D) and Discovery Support
  This initial stage involves providing specialized services to identify potential drug candidates, perform early-stage testing, and optimize drug development processes.
  Key Players: Charles River Laboratories, ICON plc (via PPD and Labcorp partnerships), and WuXi AppTec
• Active Pharmaceutical Ingredient (API) Manufacturing
  This core stage involves the production of the biologically active component of the drug product, requiring specialized chemical synthesis and processing capabilities.
  Key Players: Lonza Group, Catalent, Inc., Albemarle Corporation, and Aarti Industries Limited
• Drug Product Formulation & Manufacturing (DP) / Fill-Finish
  In this stage, the API is combined with other ingredients to create the final dosage form (tablets, capsules, injectables), and prepared for packaging through processes like aseptic fill-finish.
  Key Players: Catalent, Inc., Vetter Pharma International GmbH (specializing in injectables), Piramal Pharma Solutions, and Recipharm AB.
• Packaging, Logistics, & Supply Chain Management
  The final stage focuses on primary and secondary packaging of the finished drug products, adhering to strict labeling regulations, serialization requirements for traceability, and subsequent distribution to global markets.
  Key Players: Recipharm AB and Piramal Pharma Solutions

Competitive Landscape

The healthcare contract development and manufacturing organization (CDMO) market is regarded as semi-consolidated, as global players are competing with regional & locally established firms. There are moderate entry barriers & several reasons for companies to innovate and evolve their services constantly due to strong compliance with regulations, as well as excellent manufacturing facilities & strong relationships with long-term customers.

The top companies in the market compete in the sphere of integrated development and manufacturing services, advanced knowledge of biologics, presence on global markets, and powerful alliances with customers. The niche players in the sector focus more on sophisticated technologies and flexible manufacturing solutions. The modern trends in the CDMO industry include the consolidation of the companies by means of the mergers and acquisitions, investment in the facilities, introduction of advanced technologies and establishment of partnerships. The challenges for companies that operate in the sphere are high costs of the activity, strict regulatory requirements, presence of intellectual property protection rights, as well as growing popularity of the complex biologics products.

Key players in Healthcare Contract Development and Manufacturing Organization Market & Their Offerings

• Flex: While primarily known as a global manufacturing giant, Flex contributes to the healthcare CDMO market by leveraging its large-scale electronics manufacturing expertise for medical devices and components.
• Covance Inc.: Now the clinical research and drug development business of Labcorp, Covance contributes significantly by offering a comprehensive suite of early-stage research, clinical trial support, and central laboratory services.
• Lonza Group Ltd.: Lonza is a major global CDMO that significantly contributes to the market through its end-to-end service offering, from drug discovery to commercial manufacturing for both small molecules and biologics.
• Thermo Fisher Scientific Inc.: Thermo Fisher contributes to the CDMO market both as a key supplier of laboratory equipment and through its PPD clinical research services and Patheon commercial manufacturing brands.
• Jabil: Jabil contributes to the healthcare market primarily through its manufacturing services for medical devices, diagnostics, and pharmaceutical delivery systems, leveraging its global manufacturing footprint and expertise in complex plastics and electronics integration.
• Catalent Inc.: Catalent is a leading global CDMO that provides advanced delivery technologies and development solutions for drugs, biologics, and consumer health products.
• Sanmina Corporation: Sanmina contributes to the healthcare sector by providing integrated manufacturing solutions for complex medical and diagnostic equipment, similar to Flex and Jabil.
• IQVIA Holdings Inc.: Primarily known as a contract research organization (CRO), IQVIA contributes to the broader drug development market by providing advanced analytics, technology, and clinical trial management services. Their expertise is centered on leveraging data and human science to help
• pharmaceutical companies optimize clinical development and commercialization strategies.
• Siegfried Holding AG: Siegfried is a major CDMO specializing in the development and manufacturing of APIs and drug products for the pharmaceutical industry. They contribute by offering a range of services from chemical synthesis to secondary packaging, ensuring the reliable and quality-compliant supply of essential drug components.
• Recipharm AB: Recipharm contributes as a major European CDMO that offers manufacturing services for pharmaceutical products in various dosage forms, along with development, packaging, and logistics solutions.

Recent Developments

• In March 2025, HAS Healthcare Advanced Synthesis SA, a globally leading developer and producer of active pharmaceutical ingredients (APIs), anticancer compounds and high-potency active pharmaceutical ingredients (HPAPIs) announced the planned acquisition of a globally known manufacturer of chemical and biological APIs, Cerbios-Pharma SA. The partnership aims at creating a leading international group in the CDMO sector which is backed by 65 Equity Partners.
• In January 2025, Akums Drugs & Pharmaceuticals Ltd., India's leading Contract Development and Manufacturing Organization (CDMO), launched its new cutting-edge sterile manufacturing facility, committed to manufacture lyophilized products.
• In September 2024, CELLTRION, Inc., a biopharmaceutical company, declared the full-scale launch of its Contract Development and Manufacturing Organization (CDMO) at the “Morgan Stanley Global Healthcare Conference” held in New York.

The introduction of new products for outsourcing various processes in the pharmaceutical industry, as well as the expansion of key market competitors, are expected to drive the healthcare contract development and manufacturing organization market growth in the near future. The healthcare contract development and manufacturing organization market is expected to develop significantly in the forecast period due to the increase in acquisitions and definitive agreements made by the leading market leaders.

Segments Covered in the Report

By Services

• Contract Manufacturing
  • Preclinical
  • Bioanalysis and DMPK studies
  • Toxicology Testing
  • Other Preclinical Services
  • Clinical
  • Phase I
  • Phase II
  • Phase III
  • Phase IV
  • Laboratory Services
  • Bioanalytical Services
  • Analytical Services
  • Cell Line development
  • Process Development
    • Microbial
    • Mammalian
    • Others
    • MABs
    • Recombinant proteins
    • Others
  • Upstream
  • Downstream
  • Others
• Small Molecule
• Large Molecule
• Contract Development
  • MABs
  • Recombinant proteins
  • Others
  • Solid Dose Formulation
  • Liquid Dose Formulation
  • Injectable Dose Formulation
  • Class I
  • Class II
  • Class III
• Small Molecule
• Large Molecule
• High Potency API
• Finished Dose Formulations
• Medical Devices

By Region

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East & Africa